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DISCLOSURES AND CREDENTIALS:
Spotlight:
Perspective on a Rapid HIV Testing Program for Inmates at the Hillsborough
County Jail in Tampa, Florida
HIV 101:
New Antiretrovirals for 2007-2008
CONFERENCE COVERAGE:  THE 4TH INTERNATIONAL
AIDS SOCIETY (IAS) CONFERENCE ON HIV
PATHOGENESIS, TREATMENT AND PREVENTION
OBJECTIVES
The reader will be able to describe the most significant studies presented at the 4th International AIDS Society Conference in regards to anti-
retroviral therapy. 
The reader will be able to discuss the most significant studies presented at the 4th International AIDS Society Conference in regards to HIV and
viral hepatitis co-infection. 
The reader will be able to summarize the most significant studies presented at the 4th International AIDS Society Conference in regards to resis-
tance and tropism testing. 
The reader will be able to explain the rapid HIV testing program at the Hillsborough County Jail in Tampa, FL. 
The reader will be able to identify new antiretroviral medications. 
Rafael Campo, MD
Professor of Clinical Medicine
Division of Infectious Diseases
University of Miami School of Medicine
Introduction
The 4th International AIDS Society (IAS)
Conference on HIV Pathogenesis,
Treatment and Prevention took place in
Sydney, Australia, from 22-25 July 2007. As
the premier summer HIV conference (alter-
nating with its sister meeting, the
International AIDS Conference), the IAS
meeting is a great venue for the presenta-
tion of ground breaking HIV-related
research. New data on currently available
antiretroviral agents, the management of
medication-associated toxicities, and the
ever-evolving paradigm on when to start
therapy were presented. Most exciting were
presentations of data dealing with new anti-
retroviral agents in new drug classes.
Lastly, data on antiretroviral resistance, tro-
pism testing, and management of HIV-relat-
ed morbidities and co-infections rounded
out the meeting.  Although there were no
sessions or presentations dedicated to the
care of the incarcerated HIV-infected indi-
vidual, the results of a number of major
studies have a bearing on how HIV is treat-
ed in prisons and jails and elsewhere.
Current antiretroviral agents and treat-
ment strategies
The newest of the protease inhibitors (PIs),
darunavir (DRV), has been seen by many
as a potentially valuable addition to the HIV
armamentarium especially for the treatment
of antiretroviral experienced patients. The
TITAN study compared DRV 600 mg/riton-
avir (r) 100 mg BID (n=298) to lopinavir
(LPV) 400 mg/r 100 mg BID (n=297) over
48 weeks in antiretroviral therapy (ART)-
experienced, LPV-naïve patients.1 Both
groups of patients received an optimized
background regimen with two or more
nuceloside and/or non-nucleoside reverse
transcriptase inhibitors (NRTIs/NNRTIs).
Results are shown in Table 1. Because the
lower limit of the 95% CI did not go below -
12% for either of the two primary outcome
measures (proportion with a viral load <400
copies/ml and <50 copies/ml at 48 weeks)
for the DRV/r arm, DRV/r was shown to be
non-inferior to LPV/r. In fact, because the
lower limit of the confidence limits for both of
these endpoints did not go below 0, DRV/r
was shown to be superior to LPV/r by both
criteria.  
A related sub-study analyzed the response
according to the number of LPV-associated
resistance mutations at baseline.2 Since
none of these patients were LPV-experi-
enced, these mutations had obviously been
selected through the use of other PIs prior
to enrollment in this study.  Although a for-
mal statistical analysis was not presented,
the results suggested that the responses to
LPV/r and DRV/r are similar in patients with
virus with <6 LPV mutations (Figure 1).  Not
surprisingly, it was for virus with >6 LPV
mutations for which DRV/r seemed to be
more effective than LPV/r.  These findings
were similar to the ones stratified by pheno-
typic fold changes: The outcomes were sim-
ilar as long as the LPV fold change stayed
<10; for patients with LPV fold change
between 10 and 40, DRV/r was more effec-
tive than LPV/r. Thus, it seems that these
data can be interpreted in a relatively
straightforward fashion: for patients with
lower level PI resistance (<6 LPV mutations
and/or <10 LPV fold change on phenotypic
resistance testing) the efficacy of the two
PIs is comparable; with higher level PI resis-
tance (>6 LPV mutations or >10 LPV FC)
DRV/r appears more effective than LPV/r. 
A very interesting study by Mallal and col-
leagues dealt with the prevention of hyper-
sensitivity reactions (HSR) in patients start-
ing Abacavir (ABC) through pharmacoge-
nomic testing  ABC-naïve subjects (n=1956)
about to start an ABC-containing ART regi-
men were randomized 1:1 to either be mon-
itored for HSR through standard-of-care
observation or to undergo prospective test-
ing for HLA-B*5701.3  Previously, it had
been reported that persons with this HLA
type were more susceptible to HSR induced
by ABC. In the prospective testing arm,
those patients negative for B*5701 went on
to receive the ABC; those who tested posi-
tive did not continue participation in the
study. The endpoints of the study were clin-
ically suspected (but not immunologically
confirmed) ABC HSR and clinically suspect-
ed, immunologically confirmed ABC HSR.
The immunological confirmation was carried
out through skin patch testing, a research
tool not available clinically. The incidence of
clinically suspected ABC HSR was lower in
the prospective screening arm than the
standard-of-care arm and there were no
cases of immunologically confirmed HSR in
the prospective screening arm (Figure 2).
Thus, the negative predictive value of
B*5701 testing was 100%. The authors con-
cluded that prospective B*5701 testing
resulted in a "dramatic, clinically relevant
and statistically significant reduction in ABC
HSR". Testing for HLA-B*5701 is becoming
available in clinical labs at a cost of $100 or
less. 
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Dear Correctional Colleagues,
These are exciting times in HIV therapeutics. We are at the cusp of a major change in the treat-
ment landscape of this infection with the eminent release of three new HIV medications. Two of
these antiretrovirals use unique mechanisms to interrupt the virus life cycle and the third extends
the utility of an older class of these drugs. Together they provide, almost literally, a new lease on
life for those with multi-drug resistant HIV infection.
Too often in corrections we care for HIV-infected individuals with extensive treatment experience
who have cycled in and out of prisons, jails and the streets - along the way receiving and stop-
ping antiretrovirals. Not surprisingly, many of these individuals develop drug resistant virus that
out paces the availability of active agents in the HIV armamentarium. With genotypes dripping in
red, we scratch our heads, unsure what to do to help these people, many of whom are asking for
another chance. 
With a critical mass of recently and about to be approved potent HIV drugs it is becoming increas-
ingly possible to craft effective regimens for those with such extensive drug resistance. In this
issue of IDCR we highlight the features of the major new HIV therapies so that we in corrections
can prepare for their arrival and apply them wisely when they do come to our formularies.  We
also asked Dr. Rafael Campo of the University of Miami School of Medicine, an expert in the clin-
ical management of HIV, to report back from the International AIDS Society Meeting held in
Sydney, Australia. He provides an in-depth review of the data regarding emerging and established
HIV therapies as well as data presented on HIV and viral hepatitis co-infection.
As with any change to the standard existing procedures, correctional systems are tasked to con-
sider how these developments and advances can be incorporated in a manner that best serves
the needs of patients and is affordable. Over the coming months there will be continued discus-
sions regarding the cost of newer HIV therapies and the expensive laboratory testing that, in the
case of one of these drugs, is practically required prior to use.  
We, as well as those who represent our interests, must make a loud and unequivocal call on the
pharmaceutical and laboratory companies involved to not forget that these products will be used
extensively in correctional systems. Systems with zero-sum budgets that must cover everything
from bed sheets to Band-Aids. Prisons and jails that are often left behind when it comes to spe-
cial pricing for low income patients. Facilities that care for a lot of drug resistant HIV-infected
patients. It does no good for our colleagues in industry who spent fortunes to develop these drugs
or our patients who need these drugs to survive if new these exciting HIV therapies go unused
for the wont of a price that is fair and affordable.  
David A. Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Research Unit 
The University of North Carolina - Chapel Hill
LETTER FROM THE EDITOR
CONFERENCE COVERAGE:  THE 4TH INTERNATIONAL AIDS SOCIETY (IAS) CONFERENCE ON HIV
PATHOGENESIS, TREATMENT AND PREVENTION
P.S. New (2007) modified format on
first page is made to comply with the
ACCME requirements
Many discussions at the conference cen-
tered on the question of when to start HIV
therapy.  Data from four large cohort studies
were presented. The specific aspects of the
studies were different, but the overall mes-
sage was the same: deferral of therapy is
associated with poor outcomes. This con-
clusion was evident in CASCADE (the cur-
rent CD4+ count, the nadir CD4+ count, and
the time with CD4+ <350 were associated
with AIDS and non-AIDS-related deaths),
SMART (there was a greater risk of oppor-
tunistic infections [OIs], death/OIs, and seri-
ous non-AIDS events when ART was
deferred for treatment-naïve patients),
ATHENA (there was a slower CD4+ decline
or better increase in CD4+ numbers if ther-
apy was started with 350-500 vs. 200-350
CD4+ cells), and HOPS (there were fewer
instances of NRTI-associated toxicities with
ART initiation at higher CD4+ counts).4-7 It
seems clear that the pendulum is once
more on the swing towards earlier initiation
of therapy.  In retrospect, the reason why
clinicians had moved towards later initiation
was because of the lower efficacy, lower
genetic barrier, higher pill burden, and
greater toxicity of the ART regimens avail-
able a few years ago. With the improve-
ments in all these aspects of ART with mod-
ern regimens, it is appropriate that we re-
examine the optimal time of starting ART.
New antiretroviral agents
The first phase III 48-week data regarding
the use of maraviroc (MVC), Pfizer's CCR5
receptor blocker, in ART-naïve patients
were presented at the conference (the
MERIT study).8 Patients without resistance
to efavirenz (EFV), zidovudine (ZDV), or
lamivudine (3TC) were randomized to one
of 3 blinded treatment arms: MVC 300 mg
QD vs. MVC 300 mg BID vs. EFV 600 mg
QD, all with a backbone of co-formulated
ZDV 300 mg/3TC 150 mg (CBV) BID.
Baseline characteristics were similar for all
patients.  The MVC QD arm was stopped by
the study data and safety monitoring board
(DSMB) in January 2006 due to inferior effi-
cacy compared to the two other arms.  For
non-inferiority to be established for MVC,
the lower limit of the 1-sided 97.5% CI could
not cross -10%; by this criterion, non-inferi-
ority was proven for <400 c/ml but not for
the <50 c/ml endpoint. This means that
MVC was found not to be 'not inferior' to
EFV (i.e. it was worse) with regard to
achievement of a viral load less than 50
copies/mL. Despite the virologic data, the
mean change in CD4+ counts was statisti-
cally superior for the MVC arm. The rates of
discontinuation for MVC and EFV were sim-
ilar (26.9% and 25.2%, respectively); how-
ever, the causes for discontinuation were
different: lack of efficacy was higher with
MVC (11.9%) than with EFV (4.2%) but
adverse events were higher with EFV
(13.6%) than with MVC (4.2%). How to put
all this together?  Taking into consideration
that the lower limit of the CI was a bit more
stringent than what is typically used (-12%),
the efficacy was roughly comparable. While
EFV seemed to be more effective from a
virological suppression perspective, there is
a toxicity price to pay for this higher efficacy,
and at the end of 48-weeks this resulted in
a wash.  There is one aspect of the study
that was not presented but may prove to be
very important in the long run:  the selection
of drug resistance.  If the greater number of
MVC virological failures were accompanied
by selection of antiretroviral resistance to
MVC or other agents in the regimen but the
EFV toxicity failures were not associated
with drug resistance, then EFV may be
associated with a lesser cost for failure and
may end up being a superior drug for naïve
patients. This resistance data will undoubt-
edly be presented at a future conference.
Another CCR5 blocker, vicriviroc (VCV),
was also studied in the 48-week AIDS
Clinical Trials Group (ACTG) 5211 trial.9
ART-experienced patients with CCR5-tropic
virus and taking ritonavir-containing regi-
mens were randomized to have VCV at 5,
10, or 15 mg vs. placebo added to the fail-
ing regimen for 14 days after which an opti-
mized background regimen (OBR) was
started. Crossover from the placebo arm to
the VCV arms was allowed for patients with
virologic failure after week 16. The lowest
dose of VCV was discontinued by the study
DSMB because of lower efficacy.  As report-
ed previously, the study was eventually
unblinded because of eight malignancies
(two in the placebo and six in the VCV
arms).  The data presented suggest that the
10 mg and 15 mg arms of VCV were able to
suppress viral replication (Table 2). It is
hard to make any statements beyond that
observation because of the relatively small
number of patients in the study and the
paucity of other available information (e.g.
response according to the number of active
agents in the OBR). Future studies may
demonstrate that VCV is yet another CCR5
blocker with promising efficacy.
Another 48-week study of a new drug in
naïve patients that generated great interest
was a study of the integrase inhibitor ralte-
gravir.10 Antiretroviral-naïve patients
(n=198) were randomized to receive either
raltegravir at one of four different doses BID
(100 mg, 200 mg, 400 mg, or 600 mg) vs.
EFV 600 mg daily, all with a backbone of
tenofovir 300 mg daily and 3TC 150 mg
BID. Baseline characteristics were also sim-
ilar for all patients. All patient groups expe-
rienced >2.2 log10 viral load decreases with
similar increases in CD4+ cells. Patients
receiving raltegravir achieved a viral load
<50 copies/mL sooner than patients on
EFV, but by week 24 and through week 48
the virological responses were similar.  Drug
related adverse events were similar for all
groups except for the well-known associa-
tion of central nervous system adverse
effects with EFV. Also, there were eleva-
tions in total cholesterol and triglycerides for
EFV but not for raltegravir. Thus, it can be
concluded that raltegravir seems to be an
efficacious and well-tolerated drug in naïve
patients with an efficacy and safety profile
comparable to that of EFV.
TMC-125 (etravirine), a novel NNRTI, is
also undergoing intensive clinical testing.
Two studies identical in design and different
only with respect the region of the world
where they were conducted (DUET-1
[n=612] and DUET-2 [n=591]) were present-
ed at the conference.11,12 Patients with
documented NNRTI resistance and >3 PI
mutations were randomized to receive
TMC-125 vs. placebo plus DVR/r plus
investigator-chosen NRTIs ± enfuvirtide.  A
24-week (out of a planned 96-week study)
efficacy analysis was presented for each of
the two studies (Table 3). The incidence of
adverse events and toxicity-related treat-
ment discontinuations were similar for both
groups in both studies. The authors con-
cluded that TMC-125 is the first NNRTI to
show efficacy in patients with NNRTI resis-
tance as well as being well tolerated and
safe.
Viral hepatitis
Studies dealing with viral hepatitis are an
important component of these international
conferences, especially for correctional
health care providers. However, not as
many studies were presented on this topic
at this particular conference; nonetheless, a
few abstracts contained interesting obser-
vations and are worth noting.
Most hepatitis work in recent years has
focused on hepatitis C virus (HCV) since the
rates of co-infection with HIV are so high.
As there has been an effective vaccine for
hepatitis B virus (HBV) for the last two
decades, the number of HIV/HBV co-infect-
ed patients is not as large, but these
patients are seen among our clinic popula-
tions and frequently pose a therapeutic
challenge. An issue that complicates the
management of HBV-HIV co-infection is the
fact that patients may require treatment for
HBV but may still have high CD4+ cell val-
ues and low HIV viral loads making treat-
ment for HIV unnecessary.  Thus, the use of
agents for HBV but with activity against both
viruses (e.g. lamivudine [3TC], and emtric-
itabine [FTC]) may lead to the selection of
resistance by HIV against these agents.  At
a hepatitis symposium, Vicente Soriano
from Madrid presented a useful algorithm
for the treatment of HBV in patients who do
not yet require treatment for HIV (Figure
3).13 Although the algorithm is based on
expert opinion and would obviously need to
be individualized for any particular patient, it
is a potentially useful tool for the manage-
ment of these patients.
An issue that many HIV clinicians deal with
frequently is diminished vaccine efficacy
because of a compromised immune
response.  It has been clearly demonstrated
that response rates to HBV vaccination are
lower among HIV-infected individuals com-
pared to those without HIV infection.  Bortan
and colleagues reported a retrospective
study on the vaccination with recombinant
HBV vaccine of HIV-infected individuals
with either the standard dose (10 mcg at 0,
1, and 6 months) or a higher dose (40 mcg
at 0, 1, and 6 months).14 Although the num-
ber of patients in the study was relatively
small, the results were impressive: only
26% (11 of 42) of standard dose-vaccinees
developed anti-HBs titers >10 IU/L whereas
82% (9 of 11) of high dose-vaccinees devel-
oped these titers. The standard and high
dose vaccinees had similar CD4+ cell
counts (398 and 353, respectively) and use
of ART (88% and 91%, respectively). The
investigators could not identify by multivari-
ate analysis any factors (other than vaccine
dose) that were associated with an ade-
quate anti-HBs response. These results
suggest that it is possible to successfully
vaccinate HIV-infected individuals against
HBV infection, although a larger study
would be needed in order to establish the
optimal dose.
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In general, the efficacy of treatment for HCV
is disappointing with long-term sustained
virologic response (SVR) rates as low as 20-
30% especially among patients with HCV
genotypes 1 and 4.  A small retrospective
study from Italy suggests, however, that
even in the absence of SVR there might be
a significant benefit to pegylated interferon
(peg-IFN) and ribavirin (RBV) treatment.15
Twenty-five co-infected patients treated with
peg-IFN and RBV for a median of 9 months
but without SVR were compared to 25 co-
infected and untreated patients matched for
age, gender, and Child-Pugh score.  After a
median of 54 months of follow-up, 16%
(n=4) of treated and 52% (n=13) of untreat-
ed controls, respectively, developed a study
endpoint (death or development of ascites,
jaundice, encephalopathy, gastrointestinal
bleeding, or hepatocellular carcinoma)
(p=0.02).  By multivariate analysis the pre-
dictors of development of a study endpoint
were use of peg-IFN therapy (adjusted
RR=0.03; p=0.016) and the presence of
detectable HIV RNA (adjusted RR=35.98;
p=0.024).  Thus, there seems to be benefit
to therapy for HCV in co-infected patients -
even in the absence of viral suppression. 
Resistance and tropism testing
An observation regarding resistance testing
with useful practical consequences was
made by a group of British investigators.16
They retrospectively studied the outcome of
genotypic testing (GT) in viral load samples
with <1000 copies/ml vs. >1000 copies/ml
from patients on antiretrovirals with either
viral failure (a viral load <50 copies/ml fol-
lowed by two HIV RNA levels >50 copies/ml)
or failure to suppress (HIV RNA level >50
copies/ml after being on HIV therapy for >6
months). All 66 samples with a viral load
>1000 copies/ml could be amplified and
sequenced; remarkably, 56 of 67 (85%) of
samples with a viral load <1000 copies/ml
could also be amplified and sequenced.
This was the case with both low (200-1000
copies/ml) (38 of 42 samp les; 90% success
rate) as well as very low (50-200 copies/ml)
(18 of 25 samples; 72% success rates) viral
loads. This suggests that GT can identify the
selection of resistance mutations at HIV
RNA levels that are much lower than what
has been thought possible up until now.
The appropriate use of CCR5 receptor
blockers will be dependent on the identifica-
tion of the exact tropism of HIV. Use of
CCR5 blockers on virus that expresses the
CXCR4 receptor exclusively (X4 virus) or
both CCR5 (R5 virus) and CXCR4 receptors
(dual or mixed [D/M] populations) would not
only be associated with decreased efficacy
of CCR5 blockers but could lead to the
selection of resistance to the other drugs in
the regimen. There is a Food and Drug
Administration (FDA)-approved phenotypic
assay of tropism (Monogram Biosciences'
Trofile) with a turnaround time and cost sim-
ilar to that of the same company's
Phenosense assay. In order to improve turn-
around time and cost, several genotypic
assays for tropism have been developed.
These assays determine the genetic
sequence of the V3 loop of gp120 (respon-
sible for tropism) that is then matched
through a variety of methods (position scor-
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Table 1. 48-week virological and immunological efficacy of DRV/r vs. LPV/r plus > 2
NRTIs/NNRTIs in ART-experienced, LPV-naïve patients (intent-to-treat analysis)
Figure 1. Virological
response to DRV/r vs. LPV/r
plus > 2 NRTIs/NNRTIs after
48 weeks of therapy accord-
ing to number of LPV-associ-
ated protease mutations at
baseline
Figure 2.  Clinically suspected
and clinically suspected,
immunologically confirmed
ABC HSR (intent-to-treat
analysis)
SOC = Standard of care
Figure 3.  Treatment algo-
rithm for HIV-infected patients
with compensated hepatitis B
virus infection and CD4 cell
count >350/mm3
-
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ing matrices, neural networks, position-
based rules, etc.) to actual tropism pheno-
types.  A prediction of tropism is thus gener-
ated.
Low, et al. reported a study in which 920 V3
genotypes were analyzed by six different
methods and the predicted tropism was then
matched to the Trofile phenotype.17 The
goal of the study was to determine the sen-
sitivity and specificity of the genotypic meth-
ods. The sensitivity of ranged from 22-50%
and the specificity from 88-97% leading the
authors to conclude that these methods are
not yet adequate for predicting the X4 phe-
notypes upon which the determination of the
presence of D/M populations is made.
Thus, our ability to accurately predict tro-
pism by genotypes will be currently limited
for now.
Conclusions
This international conference, conducted
half way around the planet, yielded data that
are useful in our real world management of
HIV and associated conditions. Studies of
existing antiretrovirals help us refine our use
of these medications while trials of newer
therapies raise the prospect of continued
opportunities for improving the well-being of
our patients.  
Table 2.  Outcome of ACTG 5211 by study arm
Table 3.  Virological and immunological outcome of the DUET-1 and DUET-2 studies at 24 weeks
(intent-to-treat analysis)
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Drug Mechanismof Action
Major Features and Clinical Trials Results Refs
Raltegravir Inhibitor of HIV-1
integrase
Maraviroc
Inhibits the integrase enzyme responsible for integrating viral DNA into the cellular
genome. 
Over the first 24 weeks of the BEMCHMRK 1 and 2 trials, raltegravir when added to
optimized HIV therapy was found to significantly increase rates of viral suppression to
<50 copies/mL compared to placebo among patients with extensive ART experience.  
In a smaller study of treatment for naïve patients, raltegravir was comparable to
efavirenz in suppressing viremia to <50 copies/mL when both were co-administered
with tenofovir/lamivudine.
Etravirine
Blocks the CCR5 co-receptor on T-lymphocyte surface used by some strains of HIV to
gain entry into the cell.  Does not inhibit entry of virus tropic for the alternative CXCR4
co-receptor found on monocytes.
In the MOTIVATE trials, 44% of patients with multidrug resistant HIV screened for study
entry were found to have CXCR4 or dual/mixed tropic virus that would not be expected
to be inhibited by maraviroc.
An assay to determine if the patient harbors CCR5 tropic virus is available and is rec-
ommended prior to use of this drug.  Current assay cost is $1,960.
When used along with an optimized ART background, the drug was found to produce
significantly higher rates of viral suppression below 50 copies/mL compared to placebo
in the MOTIVATE trials.
Maraviroc was inferior to efavirenz in achieving a viral below 50 copies/mL when each
drug was combined with zidovudine/lamidudine in treatment for naïve patients enrolled
in the MERIT trials.  
This 'second generation' twice daily NNRTI has been found to be active against virus
containing major NNRTI resistance mutations including K103N and Y181C. 
Certain mutations and accumulated NNRTI resistance can reduce effectiveness of
etravirine.  
In the DUET trials, a significantly higher proportion of subjects with NNRTI and PI resis-
tant HIV achieved a viral load <50 copies/mL at 24 weeks with etravirine compared to
placebo when both were co-administered with darunavir/ritonavir as part of optimized
therapy.
Central nervous system adverse effects were no more common than that observed in
patients receiving placebo during the DUET studies.
CCR5 inhibitor
Non-nucleoside
reverse tran-
scriptase
inhibitor 
1, 2
3, 4, 5
6, 7, 8
7Bethany Weaver, DO MPH
Infectious Disease Consultant
Armor Correctional Health Services
Tampa, FL
At the Hillsborough County Jail, where the
average daily census in the first six months
of 2007 was 3915 inmates with 203 book-
ings per day and an average length of stay
of 21 days, three full-time health department
employees, rotating between two facilities
and funded by a federal grant, offer rapid
HIV and routine syphilis testing to inmates.
This is a voluntary testing program during
which the staff go to the 64 open bed, direct
supervision model pod and offer testing to
all those who are interested. When the
health department personnel arrive, an
announcement is made to inform inmates
they are there to offer free HIV and syphilis
tests.  If inmates choose to come forward for
testing, the result is given face-to-face the
same day. There are private rooms in each
housing unit so that staff can complete a
confidential pre- and post-test counseling
session, including written consent for testing
and provide link to care if the inmate is
found to be HIV positive. The health depart-
ment offers tests in the morning, performs
the rapid HIV tests at the jail clinic lab, and
then returns to the housing units in the after-
noon to give negative results. Inmates
receive HIV positive results in the clinic
where there is more confidentiality and an
opportunity for immediate referral to an HIV
specialist and psychiatry, if indicated.
Inmates sign a form stating that they
received their negative or positive results,
and the form becomes a permanent part of
the medical record. 
In the first quarter of 2007 (January-March),
a total of 1013 inmates (221 females, 792
males) were tested with a total of three men
identified as HIV positive and 16 cases of
syphilis identified. In the second quarter of
2007 (April-June), of the 828 inmates (98
females, 730 males) tested, nine men and
one woman tested HIV positive, and 13
cases of syphilis were identified. 
In addition to the program described above,
there are other opportunities for HIV testing
at the jail. Tampa Hillsborough Action Plan
(THAP), through a grant under Target
Outreach for Pregnant Women's Act
(TOPWA) offers rapid HIV testing to women
at the jail, in a similar fashion to the program
described above, two days per week.
Furthermore, if an inmate requests an HIV
test in writing or in the clinic when seeing a
provider, the test is then offered by a certi-
fied HIV counselor. There is close collabo-
ration between Armor Correctional Health
Services, who has been contracted to pro-
vide medical services at the jail since
October 2005, the Hillsborough County
Sheriff's office, members of the health
department, THAP, and Metropolitan
Charities, who provides case management
services to HIV positive inmates during and
after incarceration.
Linking an HIV positive inmate to an HIV
specialist on site allows the inmate the
opportunity to learn about HIV/AIDS; the
stage of disease based on blood work, his-
tory, and the physical exam; and risks for
transmission. If appropriate, HIV treatment
is initiated. In addition, the HIV specialist
works with the health department to link the
inmate to care in the community so that
funding for medications and medical care
can by accomplished upon release from
custody.  When possible, a three day supply
of medications, a prescription for a one
month supply of medications, and pertinent
medical records are given to the inmate
and/or case manager upon release from
custody. 
Overall, the HIV and syphilis testing pro-
grams are very well received by inmates
and detention staff. Though inmates with
HIV are not permitted to work in the kitchen,
they are not segregated by HIV status, and
results are given to them in a very confiden-
tial manner. Inmates are also told they can
receive immediate care with an HIV special-
ist if they turn out to be HIV positive. There
are some barriers to offering HIV testing in
lockdown units, mental health units, and the
infirmaries, mainly due to space and/or
inability to obtain proper informed consent
due to mental status, and we are working on
strategies around these barriers so that we
can expand this screening program.
Another challenge that occasionally occurs
is loss to follow-up when an inmate is
released from custody prior to receiving
confirmatory HIV or syphilis results, in which
case the health department makes every
effort to track down the individual in the
community. 
SPOTLIGHT: PERSPECTIVE ON A RAPID HIV TESTING PROGRAM FOR INMATES AT THE
HILLSBOROUGH COUNTY JAIL IN TAMPA, FLORIDA
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4th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Website
http://www.ias2007.org
A Guide to Antiretrovirals The Body Pro
http://www.thebodypro.com/index/treat/antiretroviral_link.html
CDC's National HIV Testing Resource Website
http://www.hivtest.org/
CDC's Revised Recommendations for HIV Testing of Adults, Adolescents,
and Pregnant Women in Health-Care Settings
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm
Community HIV/AIDS Mobilization Project
http://www.champnetwork.org/
National HIV/AIDS Clinician's Consultation Center
Warmline: National HIV Telephone Consultation Services
1-800-933-3413
PEPline: National Clincian's Post-Exposure Prophylaxis Hotline
1-888-448-4911
Perinatal Hotline: National Perinatal HIV Consultation and Referral
Services
1-888-448-8765 
Entecavir in Hepatitis B Virus (HBV)/HIV Co-Infected Patients
Supplement to the Guidelines for the Use of Antiretroviral Agents in HIV-
1-Infected Adults and Adolescents -- October 10, 2006
www.aidsinfo.nih.gov/contentfiles/EntecavirInHIV.pdf
Department of Health and Human Services 
2006 Adult and Adolescent Antiretroviral Treatment Guidelines
http://www.aidsinfo.nih.gov/guidelines/
International AIDS Society-USA Panel 
2006 Recommendations of the Treatment for Adult HIV Infection
http://jama.ama-assn.org/cgi/content/full/296/7/827
American Academy of HIV Medicine
http://www.aahivm.org/
RESOURCES
Go to www.AAHIVM.org to learn about mem-
bership, continuing education and the new
partnership with IDCR
2007 Intensive Review in
Correctional Medicine 
St. Louis, MO
September 7-8, 2007
Visit: http://www.cm-institute.org
HIV Therapy, Management &
Emerging Treatment Options
Live Satellite Video conference &
Webcast
October 3, 2007
12:30-2:30 p.m. EST
Visit: www.amc.edu/hivconference
518.262.4674 or
ybarraj@mail.amc.edu
National Conference on
Correctional Health Care
Nashville, TN
October 13-17
Visit: http://www.ncchc.org/education/
national2007.html
2007 Annual Conference: Medicine
in the Face of Addiction
Society of Correctional Physicians
(SCP)
October 14, 2007
Nashville, TN
Visit: http://www.corrdocs.org/frame-
work.php?pagetype=educonference&b
gn=1
15th Annual HIV/AIDS Update and
Border Health Summit
South Padre Island, TX 
24 to 26 October, 2007
Visit: http://www.valleyaids.org
The Liver Meeting 2007
58th Annual Meeting of the
American Association for the Study
of Liver Diseases
Boston, MA
November 2-6, 2007
Visit: https://www.aasld.org/eweb/
DynamicPage.aspx?webcode=07am
2007 United States Conference on
AIDS (USCA)
Palm Springs, CA
November 7-10, 2007
Visit: http://www.cdcnpin.org/scripts/
display/confdisplay.asp?confnbr=6149
AIDS in Culture IV: Explorations in
the Cultural History of AIDS
Mexico City
December 9-13, 2007
Visit: www.aidsinculture.org
SAVE THE
DATES
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HIV Control Efforts Should Directly Address
Incarceration
IDCR editorial board member, Rick Altice, in this editorial
in The Lancet, asserts that incarceration is one of the
major causes of the spread of HIV.  He suggests that
incarceration can lead to an increase in risk behaviors
that lead to acquisition of HIV, disrupt social networks and
prevent individuals from maintaining meaningful employ-
ment.  Additionally, incarceration can inhibit persons with
substance abuse problems from entering rehabilitation
programs. While incarceration has been framed as an
opportunity for a public health intervention in the HIV epi-
demic, it often provides inadequate treatment of the men-
tal health and substance abuse problems that foster HIV
tramsnission. Moreover, HIV-positive offenders often suf-
fer from poor continuity of HIV care upon their release
from prison. In response to this problem, Dr. Altice sug-
gests an increase in access to treatment of substance
abuse and dependence, solutions to drug-use that bal-
ance public safety and public health, advocacy for leg-
islative changes to decriminalize drug use, and activism
by communities affected by incarceration.
HIV control efforts should directly address incarceration.
Altice F. The Lancet. 2007;7:568-69.
Post-Release Case Management Services and Health-
Seeking Behavior Among HIV-Infected Ex-Offenders
Researchers from the Centers for Disease Control and
Prevention (CDC) and Health Resources and Services
Administration (HRSA) funded Corrections
Demonstration Project (CDP) explored the impact of ear-
lier post-release contact with a case manager on the post-
release health-seeking behavior of formerly incarcerated
HIV-infected individuals. The project, which is designed to
foster inter-agency collaboration between public health
departments, correctional facilities, and community-based
health providers, aims to improve continuity of care for
HIV-positive inmates after their release. All participants
were receiving some type of case management that was
initiated prior to release and continued post-release. The
study consisted of 226 ex-offenders who were interviewed
six months post-release. Of this group, 104 individuals
(46%) were met at the gate at time of prison release by a
case manager, while the remaining 122 individuals (54%)
were not. 
The study provided support for the important role of early
post-release case management, as ex-offenders who
were met at the gate demonstrated an increase in some
health-seeking behavior.  After controlling for health-seek-
ing behavior before incarceration, the researchers found
that ex-offenders who had been met at the gate were
more likely to participate in drug or alcohol treatment and
not engage in sex exchange during the six months follow-
ing their release from incarceration. This exhibition of
health-seeking behavior was tempered, however, by the
finding that early post-release case management was not
associated with reduced emergency room use or the use
of street drugs. Although the reason for this finding is
unclear, this study emphasizes the importance of early
post-release case management in improving health-seek-
ing behavior in ex-offenders.
Post-Release Case Management Services and Health-
Seeking Behavior Among HIV-Infected Ex-Offenders.
Arriola, K. et al.  Journal of Health Care for the Poor and
Underserved. 2007;18:665-74.
End-Stage Liver Disease in a State Prison Population
Researchers from the University of Texas Medical Branch
recently conducted a study to examine the prevalence,
mortality, and clinical characteristics of end-stage liver
disease (ESLD) in the Texas Department of Criminal
Justice (TDCJ) prison system. The study, analyzed the
medical data of 370,511 inmates over a 3.5 year period.
ESLD is one of the major consequences of hepatitis C
virus (HCV) infection and HIV/HCV coinfection, both of
which are known to disproportionately affect prison popu-
lations. The prevalence of ESLD in U.S. prisons is expect-
ed to rise as the prison-population ages, resulting in a
growing number of inmates who require liver transplants.  
The TDCJ prison system offers voluntary HIV testing to all
inmates upon incarceration and screens all HIV-positive
individuals for HCV-infection. As a result, most of the
inmates in the study knew their HIV status, but those who
were seronegative for HIV had only been tested for HCV
if they had self-reported risk behavior or had requested a
test. The study found that, of the 370,511 inmates studied,
484 had ESLD and 213 had died of ESLD during the
study-period. Inmates who were Hispanic, aged 40-49
years or 50 years and older, were infected with HIV or
HCV or both had an elevated risk of ESLD prevalence
and mortality. Ninety percent of inmates with ESLD either
had HCV monoinfection or HIV/HCV coinfection. Those
inmates with HIV/HCV co-infection had higher mortality
rates (64.9%) than patients with HCV mono-infection
(42.8%) or patients without HCV infection (36.7%).  These
findings reinforce the belief that HIV/HCV coinfection
accelerates the progression of HCV, resulting in
increased mortality from ESLD.  The growing prevalence
of ESLD in the correctional setting, in combination with
the high cost of liver transplants, emphasizes the need for
increased HCV prevention, education, and treatment.
Baillargeon J, Soloway RD, Paar D. End-Stage Liver
Disease in a State Prison Population. Ann Epidemiol.
2007 Aug 4; Epub ahead of print. 
Costs of Voluntary Rapid HIV Testing and Counseling
in Jails in 4 States - Advancing HIV Prevention
Demonstration Project, 2003-2006
This study sought to examine the feasibility of using rapid
HIV tests in prisons and jails by examining the costs and
outcomes of rapid HIV testing and counseling programs in
Florida, Louisiana, New York, and Wisconsin from March
1, 2004 to February 28, 2005. Correctional facilities in
these states tested 17,433 individuals for HIV during this
time period, resulting in 152 newly identified cases of HIV.
Although the costs for these tests were extremely vari-
able, the study found that the average cost of HIV testing
for HIV-negative inmates was between $29.46 and
$44.98. The cost of testing was significantly higher for
HIV-positive inmates and was estimated between $71.37
and $137.72 per inmate. The discrepancy in costs relative
to HIV serostatus is due to the extra post-test counseling
required for individuals who test positive for HIV. Most of
the cost of rapid HIV testing was due to variable costs,
including time for counseling and testing, nondurable
goods and supplies, and test kits. Fixed costs, such as the
cost of program management, training, travel, and
durable equipment, composed a smaller portion of testing
costs. Average costs for testing varied greatly depending
on the location of the correctional facility, as more rural
facilities required public health officials and counselors to
drive to distant sites. Differences in local wage rates also
contributed to the variability in costs. It is hoped that this
study's findings can be used to develop rapid HIV testing
programs in both prisons and jails across the country.
Costs of Voluntary Rapid HIV Testing and Counseling in
Jails in 4 States --- Advancing HIV Prevention
Demonstration Project, 2003-2006.  Shrestha, R. et al.
Sexually Transmitted Diseases.  2007;34(11):000-000.
FDA Approves Novel Antiretroviral Drug
The U.S. Food and Drug Administration (FDA) approved
the antiretroviral, maraviroc, for production and distribu-
tion. This FDA approval followed two controlled studies
with over 1,000 clinical trial participants, 840 of which
received maraviroc. The drug, which will be sold under
the trade name Selzentry, received a priority review by the
FDA and is the first of a new class of antiretroviral drugs
that prevent HIV from entering lymphocytes by blocking
the CCR5 co-receptor required by certain types of HIV to
gain entry into the cell. Maraviroc is approved for use in
combination with other antiretroviral drugs for the treat-
ment of adults with CCR5-tropic HIV-1, who have been
treated with other HIV medications and who have evi-
dence of elevated levels of plasma HIV. Health care
providers should exercise caution in prescribing maravi-
roc for treatment-naïve adults and pediatric, as it has not
been adequately tested in these individuals. Maraviroc's
product labeling has a boxed warning about the dangers
of liver toxicity (hepatoxicity) and possibility of heart
attack. Common side effects of the drug included cough,
fever, upper respiratory tract infections, rash, muscu-
loskeletal symptoms, abdominal pain, and dizziness.
http://www.fda.gov/bbs/topics/NEWS/2007/
NEW01677.html
Compiled by Christine Devore, IDCR Intern
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This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing Medical
Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR.  MEC is accredited by the ACCME to provide contin-
uing medical education for physicians. 
Medical Education Collaborative designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™.  The target audience for this edu-
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Objectives:
The reader will be able to describe the most significant studies presented at the 4th International AIDS Society Conference in regards to antiretroviral therapy. 
The reader will be able to discuss the most significant studies presented at the 4th International AIDS Society Conference in regards to HIV and viral hepatitis 
co-infection. 
The reader will be able to summarize the most significant studies presented at the 4th International AIDS Society Conference in regards to resistance and tro-
pism testing. 
The reader will be able to explain the rapid HIV testing program at the Hillsborough County Jail in Tampa, FL. 
The reader will be able to identify new antiretroviral medications. 
1. The TITAN study revealed that darunavir appears to be less 
effective than LPV/r for patients with higher- level PI resistance
(>6 LPV mutations or ?10 LPV FC).
TRUE or FALSE?
2. Which of the studies presented at the IAS Conference did not 
reveal that deferral of therapy is associated with poor outcomes?: 
A. SMART
B. CASCADE
C. MERIT
D. ATHENA
3. Which of the following was found to be true in the phase III 
MERIT study?:
A. Compared to the efavirenz arm, the mean change in CD4+ 
counts was statistically superior for the maraviroc arm. 
B. Lack of efficacy was lower with maraviroc. 
C. Adverse events were lower with efavirenz. 
D. The rates of discontinuation were similar between maraviroc 
and efavirenz. 
E. A and D
4. In a study by Borton and colleagues, 82% of HIV-positive patients 
who received high-dose HBV vaccine developed anti-HBs titers. 
TRUE or FALSE?
5. Which of the following is NOT a characteristic of the rapid HIV 
testing program for inmates at the Hillsborough County Jail in 
Tampa, Florida?
A. This is a voluntary HIV and syphilis rapid testing program 
operated by three health department personnel rotating 
between two facilities. 
B. Health department personnel require only verbal consent for 
HIV testing. 
C. Inmates have to sign a form stating that they received their 
results, and the inmate's sero-status is documented on their 
medical record. 
D. If an inmate requests an HIV test in writing or in the clinic 
when seeing a provider, the test is then offered by a certified 
HIV counselor. 
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COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation
Faculty
Content
How well did this activity avoid com-
mercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate 
this activity?
Excellent Very Good Good Fair Poor
II. Course Objectives 
Were the following overall course objectives met?  At the conclusion of this presentation, are you able to:
III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.
b.  Additional Comments 
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YES NO SOMEWHAT
YES NO SOMEWHAT
YES NO SOMEWHAT
YES NO SOMEWHAT
YES NO SOMEWHAT
The reader will be able to describe the most significant studies presented at the 4th International AIDS Society
Conference in regards to antiretroviral therapy. 
The reader will be able to discuss the most significant studies presented at the 4th International AIDS Society
Conference in regards to HIV and viral hepatitis co-infection. 
The reader will be able to summarize the most significant studies presented at the 4th International AIDS
Society Conference in regards to resistance and tropism testing. 
The reader will be able to explain the rapid HIV testing program at the Hillsborough County Jail in Tampa, FL. 
The reader will be able to identify new antiretroviral medications. 
